Scientists already led some of the results of the pandemic coronavirus COVID-19, named the most affected by the coronavirus city in the world. This Italian Bergamo. There, from February 20 to the end of March the death rate increased by 568 percent. In this case the local residents and the highest levels of antibodies, almost 57 percent, they found. However, Russian experts argue that it is important to find out if a man who has had COVID-19, a special type of thorn antibodies to the protein, giving the virus the key to body.
Among people who already have antibodies to coronavirus, scientists are now looking for those who have protection from infections maximum. It is of great importance to science and medicine. And it has become possible thanks to the tests that have come up in Institute Gamalei. Mass tests for antibodies, which are used for screening of immunity, reliably they just did a body with the virus. Resistance to infection indicates special antibodies. They are produced to S-protein in the corona virus, by which it penetrates into the cells. If the immune system is able to block S-protein, the pathogen simply cannot go into the cage, and therefore will not cause illness.
“the Presence of these antibodies in the blood test of the patient suggests that the person is protected from the virus if he was with him in the next meet,” explains Director of scientific research Institute of epidemiology and Microbiology named after N. Gamalei Alexander Ginzburg.
Rare footage in the bag, the scientists artificially grow those proteins of the coronavirus. Then they are applied to the tablet. And to each well is added the plasma of patients. If antibodies to the protein, the reagent will change color.
“We took this protein as a target and using immune-firmennogo analysis (IFA) conduct a search whether a person is in the blood these antibodies, which can block the penetration of the virus into cells,” says head of the laboratory of immuno-biotechnology research Institute of epidemiology and Microbiology named after N. Gamalei Alexander Shevlakov.
Nnew test-system is already widely used in hospitals. With its help estimate the plasma donor, which is then poured most difficult patients. Choose the blood, which will have a therapeutic effect.
“We have started the selection of donors on the content of these antibodies, and then to invite for a donation. Only plasma with a high content of antibodies, we believe will have the greatest clinical effect,” adds head of the Department of clinical and transfusion production and gravitational blood surgery of GBUZ “NII SP named after N. In. Sklifosovsky” Alexander Kostin.
And new tests are needed to assess the effectiveness of the vaccine. If preclinical testing of vaccinated mice just infected with the virus and observed, in clinical tests on volunteers, the first of which were the developers, the new tests will be the main proof that the vaccine works.
“we Have protective titers, the developers. When we receive permission to test a vaccine, we will use your test system to evaluate the effectiveness of the vaccine in order as you have rightly said, in order not to infect people” — emphasizes the Director of the Institute of epidemiology and Microbiology named after N. Gamalei Alexander Ginzburg.
Permission for clinical trials of vaccine you expect to get from day to day. If they are successful, then by the autumn the development can be run in mass production. It is hoped that the second wave will not begin before. There is a chance.
“Under the influence of solar radiation, which in particular includes radiation, the virus mutates. Most mutations that arise, the virus is not going to benefit,” says Alexander Ginzburg.
in addition, the immunity of the population traditionally increases in the summer due to the production of vitamin D.
